Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai Fosun Pharmaceutical , to develop and commercialize an experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback